To download a PDF of the programme click here.
For further information on this event please contact us.
Day One
Wednesday 31st May
08.30-09.30
Arrival & Registration & Poster Set-Up
SESSION 1:
OPENING SESSION I – The Denmark Session
Moderator: Denis Christensen
(CRODA Denmark, Denmark)
09.30-10.00
Welcome Talk:
‘MODERN VACCINES, ADJUVANTS & DELIVERY SYSTEMS – An Overview’
Denis Christensen
(CRODA Denmark, Denmark)
10.00-10.40
Keynote:
‘Targeting airway immunity with novel vaccine strategies’
Peter L. Andersen
(Novo Nordisk Foundation, Copenhagen, Denmark)
10.40-11.00
Coffee Break & Posters
SESSION 1:
OPENING SESSION II
Moderator: Peter L. Andersen
(Novo Nordisk Foundation, Copenhagen, Denmark)
11.00-11.30
Keynote:
‘Formulation and delivery of RNA vaccines: The carrier is key’
Camilla Foged
(University of Copenhagen, Copenhagen, Denmark)
11.30-12.00
‘Defining the next Generation of Adjuvants‘
Derek O’Hagan
(GSK, Cambridge, Massachusetts, USA)
12.00-12.30
‘Securing the supply chain for vaccine adjuvants in the future’
Denis Christensen
(CRODA Denmark, Denmark)
12.30-13.30
Lunch & Posters
SESSION 2:
ADJUVANTS
Moderator: Gabriel Pedersen
(Statens Serum Institut, Copenhagen, Denmark)
13.30-14.10
Keynote:
‘Vaccine adjuvants as key tools for improving pandemic preparedness’
Ali Harandi
(University of Gothenburg, Gothenburg, Sweden / University of British Columbia, Vancouver BC, Canada)
14.10-14.40
‘Engineered design of mucosal adjuvants’
Bingbing Sun
(Dalian University of Technology, Dalian City, Liaoning, China)
14.40-15.10
‘Pre-clinical optimization of adjuvant formulation, route, and regimen of SARS-SoV-2 subunit vaccine’
Will Lykins
(AAHI, Access to Advanced Health Institute, Seattle, Washington, USA)
15.10-15.30
Tea Break & Posters
SESSION 3:
VACCINE ADJUVANTS
Moderator: Derek O’Hagan
(GSK, Cambridge, Massachusetts, USA)
15.30-16.00
‘Cationic liposome-based adjuvants for transmission-blocking vaccines against SARS-CoV-2’
Gabriel Pedersen
(Statens Serum Institut, Copenhagen, Denmark)
16.00-16.30
‘Designing and formulating vaccine adjuvant systems with saponins’
Laurent Duroux
(CRODA Denmark, Denmark)
16.30-17.00
‘Natural QS21: Approved, Abundant and Available’
Rodrigo Otero and Damian Hiley
(Desert King International, San Diego, California, USA)
17.00
MVADS 2023 Welcome Reception
Sponsored by the Novo Nordisk Foundation
Day Two
Thursday 1st June 2023
SESSION 4:
ADJUVANTS
Moderator: Ed Lavelle
(Trinity College Dublin, Dublin, Ireland)
09.00-09.30
‘Can diABZI STING agonist become next best-in-class vaccine adjuvant?’
Stephane Temmerman
(GSK, Rixensart, Belgium)
09.30-10.00
‘Using the CAF01 adjuvant in vaccines against Chlamydia trachomatis’
Nina Nguyen
(Statens Serum Institut, Copenhagen, Denmark)
10.00-10.20
‘Transdifferentiating Th17 cells to a non-IL-17 expressing phenotype using liposomal adjuvants’
Katharina Wørzner
(Statens Serum Institut, Copenhagen, Denmark)
10.20-10.40
‘LNP design for MRNA vaccine delivery’
Dwain van Zyl
(CureVac, Tubingen, Germany)
10.40-11.00
Coffee Break & Posters
SESSION 5:
VACCINES/ADJUVANTS
Moderator: Zoltan Beck
(Pfizer Inc., Pearl River, New York, USA)
11.00-11.30
‘Vaccination against peanut-allergy’
Martin Bachmann
(Inselspital, Berne, Switzerland)
11.30-12.00
‘Development of iDNA vaccines against Alphaviruses and other emerging viruses‘
Peter Pushko
(MEDIGEN Inc., Frederick, Maryland, USA)
12.00-12.30
‘Matrix-M adjuvant: A key component in several novel vaccine candidates’
Linda Stertman
(Novavax AB, Uppsala, Sweden)
12.30-13.30
Lunch Break & Posters
SESSION 6:
IMMUNITY
Moderator: Martin Bachmann
(Inselspital Berne, Switzerland / University of Oxford, Oxford, UK)
13.30-14.00
‘The role of interferons and inflammasomes in adjuvant induced cellular immunity’
Ed Lavelle
(Trinity College Dublin, Dublin, Ireland)
14.00-14.30
‘scRNA-seq analysis identifies early transcriptional differences in the draining lymph node between different adjuvant systems’
Julie Zimmermann
(Statens Serum Institut, Copenhagen, Denmark)
14.30-14.50
‘Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta Spike VLP vaccine in New Zealand white rabbits’
Martha M. O’Kennedy1, Celia Abolnik2, Tanja Smith2, Thopisang Motlou3,4, Kruger Goosen5, Kamogelo M. Sepotokele2, Robyn Roth1, Ilse du Preez1, Alma Truyts1, Hester C Stark2, Martin Magwaza6, Osborn Mahanjana7, Jan A. Verschoor8, Penny L. Moore3,4 and Yolandy Lemmer1
( 1 Council for Scientific and Industrial Research (CSIR) Next Generation Health, Pretoria, South Africa. 2 Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria (UP), South Africa. 3 SA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa. 4 National Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, South Africa. 5 La-Bio Research Animal Laboratory (a Division of Disease Control Africa), Pretoria, South Africa. 6 Tautomer Pty Ltd., Centurion, South Africa. 7 3Sixty Biopharmaceuticals Pty Ltd., Gauteng, South Africa. 8 Emeritus Professor and consultant, Department of Biochemistry, Genetics and Microbiology, University of Pretoria, South Africa.)
14.50-15.10
‘The influence of spray drying carriers on powder properties of dried CAF04 liposomes’
Anitta Lutta
(Statens Serum Institut, Copenhagen, Denmark)
15.10-15.30
Tea Break & Posters
SESSION 7:
GENERAL
Moderator: Dennis Christensen
(CRODA Denmark, Denmark)
15.30-15.50
‘How to evaluate Adjuvants’
Derek O’Hagan
(GSK, Cambridge, Massachusetts, USA)
15.50-16.20
‘Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice’
Martha M. O’Kennedy1, Peter Coetzee2, Otto Koekemoer2, Lissinda du Plessis3, Carina Lourens4, Lusisizwe Kwezi5, Ilse du Preez1, Sipho Mamputha1, Daria A. Rutkowska1, Jan A. Verschoor6 and Yolandy Lemmer1
( 1 Council for Scientific and Industrial Research (CSIR) Next Generation Health, Pretoria, South Africa. 2 Onderstepoort Biological Products SOC Ltd, Onderstepoort, South Africa. 3 Centre of Excellence for Pharmaceutical Sciences (PharmacenTM), North-West University, Potchefstroom, South Africa. 4 Department of Veterinary Tropical Diseases, University of Pretoria, Onderstepoort, South Africa. 5 Council for Scientific and Industrial Research (CSIR) Chemical cluster, Pretoria, South Africa. 6 Emeritus Professor and consultant, Department of Biochemistry, University of Pretoria}
16.20-16.40
‘LNPs for RNA delivery’
Stephen Rumbelow
(Croda Inc., Plainsboro, New Jersey, USA)
16.40-17.00
‘TRANSVAC – The vaccine infrastructure – Past, present and future (?)‘
Stefan Jungbluth
(EUVaccine Initiative, Heidelberg, Germany)
Day Three
Friday 2nd June 2023
SESSION 8:
GENERAL
Moderator: Ali Harandi
(University of Gothenburg, Gothenburg, Sweden / University of British Columbia, Vancouver BC, Canada)
09.00-09.30
‘Influenza adjuvanted vaccine, assays for immunogenicity evaluation’
Emanuele Montomoli
(University of Siena/VisMederi SrL, Siena, Italy
09.30-10.00
‘Nonclinical safety assessments of a novel synthetic toll-like receptor 4 agonist and saponin based adjuvant’
Patrick Syntin
(Sanofi Pasteur, Lyon, France)
10.00-10.30
‘Nanoalum adjuvant’s kinetic and activity on Dendritic Cells’
Arianna Raponi1, James M. Brewer1, Paul Garside1 and Daniela Stranges2
( 1 School of Infection and Immunity, University of Glasgow, Scotland, UK; 2 GSK, Technical and Research Development – Drug Product, Siena, Italy)
10.30-11.00
Coffee Break & Posters
SESSION 9:
Moderator: Gabriel Pedersen
(Statens Serum Institut, Copenhagen, Denmark)
11.00-11.45
Keynote Presentation:
‘Understanding adjuvant basic immunology to direct rational adjuvant discovery’
James Brewer, Hannah Scales, Larissa Camargo da Rosa and Utku Gunes
(University of Glasgow, Glasgow, Scotland, UK)
11.45-12.15
‘Novel TLR7 adjuvants’
Akihisa Fukushima
(Sumitomo Pharma Co., Ltd., Osaka, Japan)
12.15-12.45
‘A novel adjuvant formulation induces robust Th1/Th17 memory and mucosal recall responses in Non-Human Primates’
Rasmus Mortensen
(Statens Serum Institut, Copenhagen, Denmark)
12.45-13.00
‘CMS adjuvant: Carbohydrate fatty acid monosulphate esters are potent adjuvant molecules’
Peter Paul Platenburg and Luuk Hilgers
(LiteVax BV, Oss, The Netherlands)
13.00-14.00
Lunch & Poster Breakdown
SESSION 10:
PANEL DISCUSSION
Moderators:
Gabriel Pedersen (Statens Serum Institut, Copenhagen, Denmark)
Derek O’Hagan (GSK, Cambridge, Massachusetts, USA)
Ed Lavelle (Trinity College Dublin, Dublin, Ireland)
Zoltan Beck (Pfizer Inc., Pearl River, New York, USA)
James Brewer (University of Glasgow, Glasgow, Scotland, UK)
14.45-15.00
‘Closing summary & review of MVADS 2023 Conference’
Gabriel Pedersen
(Statens Serum Institut, Copenhagen, Denmark)
15.00
Departure
Poster Session
Poster 101
‘MONTANIDE™ ISA 51 VG: Development of an automated emulsification process to provide emulsions equivalent to manual i-connector process for therapeutic vaccines’
Matthieu Bricaud1, Dorine Hello1, Claire Guilhot2, Léa Simon2, Dorothée Pliszczak2, Sabine Maraval2 and Hocine Nouari1
( 1 SEPPIC SA, Paris La Défense, La Garenne Colombes Cedex, France; 2 SEPPIC, Castres Cedex, France)
Poster 102
‘CMS adjuvant: Carbohydrate fatty acid monosulphate esters are potent adjuvant molecules’
Peter Paul Platenburg and Luuk Hilgers
(LiteVax BV, Oss, The Netherlands)
Poster 103
‘LNP design for MRNA vaccine delivery’
Dwain van Zyl
(CureVac, Tubingen, Germany)
This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.